UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 122

Sortiert nach

Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

Current psychiatry reports, 2012-08, Vol.14 (4), p.376-390

2012

Link zum Volltext

Verfügbarkeit prüfen

Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders

Neuropsychopharmacology (New York, N.Y.), 2021-03, Vol.46 (4), p.844-850

2021

Link zum Volltext

Verfügbarkeit prüfen

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease

Journal of neuroinflammation, 2017-08, Vol.14 (1), p.164-164, Article 164

2017

Link zum Volltext

Verfügbarkeit prüfen

Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications

Psychiatric services (Washington, D.C.), 2007-09, Vol.58 (9), p.1187-1192

2007

Link zum Volltext

Verfügbarkeit prüfen

Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies

Human psychopharmacology, 2013-09, Vol.28 (5), p.495-505

2013

Link zum Volltext

Verfügbarkeit prüfen

Drug-drug interactions with the use of psychotropic medications. Interview by Diane M. Sloan

CNS spectrums, 2009-08, Vol.14 (8 Suppl Q and A Forum), p.1

Ereshefsky, Larry

2009

Link zum Volltext

Verfügbarkeit prüfen

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients

Science translational medicine, 2016-11, Vol.8 (363), p.363ra150

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and drug interactions: update for new antipsychotics

The journal of clinical psychiatry, 1996, Vol.57 Suppl 11, p.12

Ereshefsky, L

1996

Link zum Volltext

Verfügbarkeit prüfen

Quantitative EEG as a translational measure for the assessment of ATH‐1017 neurophysiological changes in mild‐to‐moderate Alzheimer’s disease

Alzheimer's & dementia, 2021-12, Vol.17 (S5), p.n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic criteria for apathy in neurocognitive disorders

Alzheimer's & dementia, 2021-12, Vol.17 (12), p.1892-1904

2021

Link zum Volltext

Verfügbarkeit prüfen

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease

Journal of Alzheimer's disease, 2017-01, Vol.55 (3), p.1039

2017

Link zum Volltext

Verfügbarkeit prüfen

PROOF OF PRINCIPLE AND BIOMARKER STUDIES SPEED TRANSITION TO POC

Schizophrenia research, 2008, Vol.102 (1), p.43-44

Ereshefsky, Larry

2008

Link zum Volltext

Verfügbarkeit prüfen

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

The Journal of neuroscience, 2011-11, Vol.31 (46), p.16507-16516

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic

The journal of clinical psychiatry, 1999, Vol.60 Suppl 10, p.20

Ereshefsky, L

1999

Link zum Volltext

Verfügbarkeit prüfen

Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders

Alzheimer's & dementia, 2023-12, Vol.19 (S18)

2023

Link zum Volltext

Verfügbarkeit prüfen

Defining and assessing adherence to oral antipsychotics : A review of the literature

Schizophrenia bulletin, 2006-10, Vol.32 (4), p.724-742

2006

Link zum Volltext

Verfügbarkeit prüfen

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

Journal of clinical psychopharmacology, 1999-04, Vol.19 (2), p.155-163

1999

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study

The journal of clinical psychiatry, 2008-10, Vol.69 (10), p.1557

2008

Link zum Volltext

Verfügbarkeit prüfen

S35. THE PLACEBO CONUNDRUM: MITIGATING THE RESPONSE AT THE SITE LEVEL

Schizophrenia bulletin, 2020-05, Vol.46 (Supplement_1), p.S45-S45

2020

Link zum Volltext

Verfügbarkeit prüfen

Experimental Medicine Approaches in Early-Phase CNS Drug Development

Advances in neurobiology, 2023, Vol.30, p.417-455

2023

Link zum Volltext

Verfügbarkeit prüfen

What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

Schizophrenia bulletin, 2010-05, Vol.36 (3), p.504-509

2010

Link zum Volltext

Verfügbarkeit prüfen

P4‐357: EFFECTS OF SCOPOLAMINE ON WORKING MEMORY TASK AND RESTING FUNCTIONAL CONNECTIVITY USING FMRI IN HEALTHY KOREAN SUBJECTS

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_16)

2014

Link zum Volltext

Verfügbarkeit prüfen

PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF LY3202626, A NOVEL BACE1 INHIBITOR, IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER’S DISEASE

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P418-P418

2016

Link zum Volltext

Verfügbarkeit prüfen

Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers

Psychopharmacology, 2016-07, Vol.233 (13), p.2429-2439

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(82)

Publikationsform

Sprache

Englisch
(122)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(69)
Science & Technology
(63)
Life Sciences & Biomedicine
(62)
Psychiatry
(37)
Pharmacology & Pharmacy
(33)
Female
(32)
Male
(32)
Adult
(31)
Schizophrenia - Drug Therapy
(27)
Biological And Medical Sciences
(26)
Medical Sciences
(26)
Pharmacology. Drug Treatments
(22)
Middle Aged
(20)
Neuropharmacology
(19)
Psychology. Psychoanalysis. Psychiatry
(19)
Psychopharmacology
(19)
Drug Interactions
(17)
Neurology
(14)
Antipsychotic Agents - Therapeutic Use
(13)
Dose-Response Relationship, Drug
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease

Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications

Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies

Drug-drug interactions with the use of psychotropic medications. Interview by Diane M. Sloan

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients

Pharmacokinetics and drug interactions: update for new antipsychotics

Quantitative EEG as a translational measure for the assessment of ATH‐1017 neurophysiological changes in mild‐to‐moderate Alzheimer’s disease

Diagnostic criteria for apathy in neurocognitive disorders

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease

PROOF OF PRINCIPLE AND BIOMARKER STUDIES SPEED TRANSITION TO POC

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic

Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders

Defining and assessing adherence to oral antipsychotics : A review of the literature

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans

Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study

S35. THE PLACEBO CONUNDRUM: MITIGATING THE RESPONSE AT THE SITE LEVEL

Experimental Medicine Approaches in Early-Phase CNS Drug Development

What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

P4‐357: EFFECTS OF SCOPOLAMINE ON WORKING MEMORY TASK AND RESTING FUNCTIONAL CONNECTIVITY USING FMRI IN HEALTHY KOREAN SUBJECTS

PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF LY3202626, A NOVEL BACE1 INHIBITOR, IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER’S DISEASE

Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers

Suchergebnisse filtern